Sun Pharma has received FDA approval for its ophthalmology NDA, BromSite (0.075% bromfenac), the first such non-steroidal anti-inflammatory drug (NSAID ) cleared by the agency to prevent pain and treat inflammation in cataract surgery patients.
Scrip had earlier indicated how the BromSite approval could set the stage for a push in the ophthalmology segment...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
